NasdaqCM - Nasdaq Real Time Price USD
Venus Concept Inc. (VERO)
As of 3:08 PM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
69,809.0000
--
99,497.0000
105,622.0000
78,014.0000
110,406.0000
Cost of Revenue
22,065.0000
--
33,526.0000
31,528.0000
26,623.0000
33,753.0000
Gross Profit
47,744.0000
--
65,971.0000
74,094.0000
51,391.0000
76,653.0000
Operating Expense
75,496.0000
--
100,847.0000
91,636.0000
91,839.0000
106,931.0000
Operating Income
-27,752.0000
--
-34,876.0000
-17,542.0000
-40,448.0000
-30,278.0000
Net Non Operating Interest Income Expense
-8,570.0000
--
-4,561.0000
-4,955.0000
-8,343.0000
-7,846.0000
Other Income Expense
-13,754.0000
--
-4,869.0000
-351.0000
-32,846.0000
-2,314.0000
Pretax Income
-50,076.0000
--
-44,306.0000
-22,848.0000
-81,637.0000
-40,438.0000
Tax Provision
-317.0000
--
-722.0000
-707.0000
1,181.0000
1,857.0000
Net Income Common Stockholders
-49,929.0000
--
-43,700.0000
-23,013.0000
-85,270.0000
-40,619.0000
Diluted NI Available to Com Stockholders
-49,929.0000
--
-43,700.0000
-23,013.0000
-85,270.0000
-40,619.0000
Basic EPS
-8.46
-6.84
-9.90
-6.30
-34.95
--
Diluted EPS
-8.46
-6.84
-9.90
-6.30
-34.95
--
Basic Average Shares
5,859.0000
5,442.0000
4,397.3330
3,631.0660
2,441.7330
--
Diluted Average Shares
5,859.0000
5,442.0000
4,397.3330
3,631.0660
2,441.7330
--
Total Operating Income as Reported
-27,752.0000
--
-34,876.0000
-14,767.0000
-67,898.0000
-30,278.0000
Rent Expense Supplemental
3,749.0000
4,312.0000
9,435.0000
10,459.0000
7,899.0000
--
Total Expenses
97,561.0000
--
134,373.0000
123,164.0000
118,462.0000
140,684.0000
Net Income from Continuing & Discontinued Operation
-49,929.0000
--
-43,700.0000
-23,013.0000
-81,706.0000
-40,619.0000
Normalized Income
-36,262.0680
--
-38,910.3441
-22,672.8612
-57,728.4200
-38,929.7800
Interest Expense
8,570.0000
--
4,561.0000
4,955.0000
8,343.0000
7,846.0000
Net Interest Income
-8,570.0000
--
-4,561.0000
-4,955.0000
-8,343.0000
-7,846.0000
EBIT
-41,506.0000
--
-39,745.0000
-17,893.0000
-73,294.0000
-32,592.0000
EBITDA
-37,471.0000
--
-35,282.0000
-13,039.0000
-68,490.0000
-30,552.0000
Reconciled Cost of Revenue
22,065.0000
--
33,526.0000
31,528.0000
26,623.0000
33,753.0000
Reconciled Depreciation
4,035.0000
--
4,463.0000
4,854.0000
4,804.0000
2,040.0000
Net Income from Continuing Operation Net Minority Interest
-49,929.0000
--
-43,700.0000
-23,013.0000
-81,706.0000
-40,619.0000
Total Unusual Items Excluding Goodwill
-13,754.0000
--
-4,869.0000
-351.0000
-32,846.0000
-2,314.0000
Total Unusual Items
-13,754.0000
--
-4,869.0000
-351.0000
-32,846.0000
-2,314.0000
Normalized EBITDA
-23,717.0000
--
-30,413.0000
-12,688.0000
-35,644.0000
-28,238.0000
Tax Rate for Calcs
0.0000
--
0.0000
0.0000
0.0003
0.0003
Tax Effect of Unusual Items
-87.0680
--
-79.3441
-10.8612
-8,868.4200
-624.7800
12/31/2019 - 10/12/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BJDX Bluejay Diagnostics, Inc.
0.1042
+4.71%
NUWE Nuwellis, Inc.
1.7950
+9.45%
TIVC Tivic Health Systems, Inc.
0.3070
+2.37%
RSLS ReShape Lifesciences Inc.
5.37
-5.36%
NAYA NAYA Biosciences, Inc.
0.8501
-3.40%
AIMD Ainos, Inc.
0.5640
+4.43%
BBLG Bone Biologics Corporation
1.7200
0.00%
BSGM BioSig Technologies, Inc.
0.8200
0.00%
TBIO Telesis Bio, Inc.
1.6000
-5.88%
INVO NAYA Biosciences, Inc.
0.8330
-2.00%